Subclinical hypothyroidism — a TSH between 4.5 and 10 mIU/L with normal Free T4 — affects 10 to 15 percent of Indian adults on a single test, and most of them are put on lifelong Thyronorm within hours of the result. The 2017 TRUST trial in the New England Journal of Medicine, the 2019 BMJ Rapid Recommendations, and the Indian Thyroid Society 2021 consensus all agree this is overtreatment. About 60 percent of mildly elevated TSH readings normalise spontaneously within 6 to 24 months. Outside of specific scenarios — TSH above 10, pregnancy, infertility, or significant symptoms with positive antibodies — Thyronorm rarely helps. This is the evidence-based guide to when to start, when to wait, and how to de-escalate if you were started inappropriately.
Subclinical Hypothyroidism in Plain English
The term causes more confusion than clarity. Let us define it precisely.
Subclinical hypothyroidism is a biochemical state in which:
- TSH is mildly elevated (4.5 to 10 mIU/L by most guidelines)
- Free T4 is within the laboratory’s normal range
- The patient may or may not have symptoms
It is not a disease in the usual sense. It is a laboratory pattern that suggests the pituitary is pushing the thyroid a little harder than baseline. The thyroid is still producing enough hormone to keep the body functioning normally.
For a complete picture of what each thyroid number means in different patterns, see the thyroid problems pillar guide.
Subclinical Hypothyroidism vs Overt Hypothyroidism
| Pattern | TSH | Free T4 | Symptoms | Treatment |
|---|---|---|---|---|
| Normal | 0.4 to 4.5 | Normal | None | None |
| Subclinical hypothyroidism | 4.5 to 10 | Normal | None to mild | Usually watch, not treat |
| Mild overt hypothyroidism | 10 to 20 | Low-normal to low | Variable | Treat |
| Severe overt hypothyroidism | Above 20 | Low | Significant | Treat |
| Myxoedema (emergency) | Often above 50 | Very low | Profound | Urgent hospitalisation |
The key distinguishing feature of subclinical hypothyroidism is normal Free T4. The thyroid is still meeting demand. The pituitary is just working harder to keep it that way.
Why So Many Indians Are Put on Thyronorm Unnecessarily
In Indian primary care, a TSH report showing 5.5 mIU/L with an “H” next to it typically results in a prescription for Thyronorm 25 within the same consultation. This pattern is so widespread that the Indian Thyronorm market — over ₹6,000 crore per year — runs largely on this exact patient cohort.
Several factors drive this overtreatment.
1. The Lab Report Says “Abnormal”
Most Indian labs use 4.5 mIU/L as the upper limit of TSH. Anything above this is flagged with a high marker. Doctors trained to treat abnormal lab values without contextual interpretation react reflexively. The 2017 TRUST trial finding that this category does not benefit from treatment has not yet penetrated routine practice.
2. The TSH Diurnal Variation Is Ignored
TSH peaks in the early morning and drops by 30 to 50 percent in the afternoon. A TSH of 5.2 at 8 AM is the same physiological state as a TSH of 3.4 at 3 PM. Few clinics ask when the sample was drawn before making treatment decisions.
3. The Repeat Test Is Skipped
About 60 percent of single mildly elevated TSH readings normalise on a second test 6 to 8 weeks later. Stress, recent viral illness, biotin supplements, and lab assay drift all cause transient elevations. Skipping the repeat is the single largest source of inappropriate Thyronorm prescriptions.
4. The Anti-TPO Question Is Not Asked
A patient with TSH 5.5 and negative anti-TPO has a very different prognosis from one with TSH 5.5 and positive anti-TPO. The first is unlikely to progress; the second is much more likely to become overtly hypothyroid over years. Without anti-TPO data, treatment decisions are made in the dark.
5. Lifelong Continuation by Default
Once Thyronorm is started, it is rarely re-evaluated for de-escalation. Patients continue for decades on doses that were never justified by trial-based evidence.
The 11 supplement, timing, and assay factors that further confound a single TSH reading are covered in the thyroid normal range and when to test guide.
What the Evidence Actually Shows
Three major trials and two systematic reviews shape the current evidence base for subclinical hypothyroidism.
The TRUST Trial (2017, NEJM)
The most important trial in this field. Stott and colleagues randomised 737 community-dwelling adults aged 65 and older with subclinical hypothyroidism (TSH 4.6 to 19.9) to either levothyroxine titrated to a target TSH or placebo. Patients were followed for one year.
Primary outcomes:
- Change in hypothyroid symptom score on the ThyPRO questionnaire: no significant difference between groups
- Change in fatigue score: no significant difference
- Change in cognitive function: no significant difference
- Change in handgrip strength: no significant difference
- Change in body weight: no significant difference
Secondary outcomes:
- Cardiovascular events: no significant difference at 1-year follow-up
- All-cause mortality: no significant difference
The conclusion was unambiguous: routine levothyroxine treatment in older adults with subclinical hypothyroidism does not improve symptoms or quality of life.
The IEMO 80-Plus Trial (2019, JAMA)
Mooijaart and colleagues did a similar trial in even older adults (80 and above) with subclinical hypothyroidism. The results matched TRUST — no symptom or quality of life benefit from treatment.
BMJ Rapid Recommendations (2019)
Bekkering and colleagues produced a guideline based on meta-analysis of all available trials. The recommendation: do not routinely treat subclinical hypothyroidism in adults regardless of age, except in pregnancy or planning pregnancy. This was a strong recommendation against routine treatment based on moderate certainty evidence.
Subclinical Hypothyroidism in Younger Adults
The trial evidence is weaker in adults under 65 because most randomised trials focused on older populations. Observational data suggest that younger adults with persistent TSH above 7 and positive anti-TPO are more likely to progress to overt disease, and a trial of Thyronorm may be reasonable. For TSH between 4.5 and 7 with negative antibodies, watchful waiting remains the dominant evidence-based approach.
Cardiovascular Outcomes Meta-Analysis
Rodondi and colleagues pooled individual participant data from 11 prospective cohorts. The finding: subclinical hypothyroidism with TSH above 10 was associated with modestly increased coronary heart disease and heart failure events. For TSH between 4.5 and 10, the association was small and inconsistent. The clinical takeaway: treat TSH above 10 if other criteria support it, but TSH 4.5 to 10 should not be treated for cardiovascular protection.
When Treatment Is Actually Indicated
These are the scenarios where the evidence supports starting Thyronorm even at TSH below 10.
1. Pregnancy or Planning Pregnancy
This is the strongest indication. Trimester-specific TSH cutoffs are:
| Stage | Treat If TSH Above |
|---|---|
| Pre-conception | 2.5 mIU/L |
| First trimester | 2.5 mIU/L |
| Second trimester | 3.0 mIU/L |
| Third trimester | 3.0 mIU/L |
Untreated subclinical hypothyroidism in pregnancy increases miscarriage risk by 1.7 to 2.5 times, preterm delivery risk, and may affect fetal neurodevelopment. The risk-benefit clearly favours treatment in this group. For pregnancy-specific management, see the thyroid in pregnancy guide.
2. Infertility Evaluation or Recurrent Pregnancy Loss
TSH should be under 2.5 mIU/L before any fertility treatment cycle. Anti-TPO positive women with subclinical hypothyroidism have higher miscarriage rates even with TSH below 4.5. Treating to TSH under 2.5 is standard.
3. TSH Above 10 mIU/L
Above 10, both cardiovascular and progression-to-overt-disease risk are higher. Confirmed TSH above 10 on a repeat test in any age group warrants treatment.
4. Significant Symptoms with Positive Anti-TPO
A patient with TSH 5.5, positive anti-TPO antibodies, and persistent fatigue not explained by other causes may benefit from a 3 to 6 month trial of Thyronorm. The threshold for stopping the trial: if symptoms do not improve with TSH brought into the lower normal range, Thyronorm is not the answer and should be tapered.
5. Goitre with Symptoms
Subclinical hypothyroidism with a clinically visible goitre, especially with compressive symptoms (difficulty swallowing, change in voice), warrants treatment to shrink the goitre.
6. Coexisting Bipolar Disorder on Lithium
Lithium causes subclinical hypothyroidism in 20 to 30 percent of users. Treatment is recommended even at TSH 4.5 to 10 because uncorrected hypothyroidism worsens depressive episodes.
When Watchful Waiting Is the Right Answer
For everyone outside the above six scenarios, the evidence supports monitoring rather than medication.
The watchful waiting protocol:
- Confirm the result with a repeat TSH 6 to 8 weeks later, same lab, same time of day (between 7 and 9 AM), off biotin supplements for at least 72 hours
- If repeat TSH normalises, monitor annually
- If repeat TSH is still elevated, add Free T4 and anti-TPO to the next test
- If Free T4 is normal and anti-TPO is negative, monitor every 6 to 12 months
- If Free T4 drops below the normal range or symptoms develop, reconsider treatment
- If anti-TPO is strongly positive (above 200 IU/mL), monitor every 6 months and counsel about higher progression risk
What to monitor between tests:
- New symptoms — fatigue, weight gain, cold intolerance, hair fall, brain fog
- Pregnancy planning — switch to immediate treatment if planning conception
- New medications — lithium, amiodarone, interferon shift the balance
- Goitre development or growth
Watchful waiting is not the same as ignoring the result. It is structured monitoring that catches genuine progression while avoiding unnecessary medication.
The Anti-TPO Decision Point
Anti-TPO antibody status is the single most important data point for deciding whether to monitor or treat subclinical hypothyroidism.
| Anti-TPO Status | Progression to Overt Hypothyroidism per Year | Implication |
|---|---|---|
| Negative | 1 to 2 percent | Likely transient or non-autoimmune cause; monitor annually |
| Borderline (35 to 60 IU/mL) | 3 to 5 percent | Likely early autoimmune; monitor every 6 months |
| Positive (60 to 200 IU/mL) | 4 to 6 percent | Established Hashimoto’s; monitor closely |
| Strongly positive (above 200 IU/mL) | 6 to 12 percent | High progression risk; consider treatment if TSH approaches 7 |
The American Thyroid Association has shifted toward treating anti-TPO positive subclinical hypothyroidism more aggressively if symptoms are present, while the Endocrine Society remains more conservative. The Indian Thyroid Society sits between these positions.
For the link between anti-TPO and Hashimoto’s, and how this affects PCOS management, see the PCOS test checklist — 22.5 percent of Indian PCOS patients have coexisting Hashimoto’s.
What Happens If You Are Started on Thyronorm Inappropriately
If you were started on Thyronorm at TSH 5 or 6 without the criteria above, you are not alone. Roughly 30 to 40 percent of Thyronorm prescriptions in Indian primary care fall into this category. De-escalation is possible but should be done under monitoring.
The Risks of Unnecessary Thyronorm
- Atrial fibrillation risk increases by 12 to 20 percent even at modest Thyronorm doses that suppress TSH below 0.4
- Postmenopausal bone density loss accelerates with over-replacement
- Insomnia, palpitations, anxiety from mild iatrogenic hyperthyroidism
- Drug interaction burden — Thyronorm interacts with calcium, iron, antacids, oral contraceptives
- Lifelong medical visits and lab costs for a non-disease
The De-Escalation Protocol
- Discuss with your treating doctor or an endocrinologist before stopping. Do not stop abruptly.
- Get a baseline TSH and Free T4 on your current dose. This is the reference point.
- Halve the dose for 6 to 8 weeks. If you are on Thyronorm 50, drop to 25. If on 25, take 25 every other day.
- Recheck TSH and Free T4 at 6 to 8 weeks. If TSH stays in normal range and Free T4 is adequate, continue tapering.
- Halve again for the next 6 to 8 weeks if labs remain normal.
- Final stop trial: stop the medication entirely. Recheck TSH and Free T4 at 6 weeks and 12 weeks.
- If TSH normalises off medication, you were on Thyronorm without need. Annual monitoring is enough.
- If TSH rises back above 10, restart Thyronorm — you had genuine hypothyroidism. About 30 percent of patients on inappropriately started Thyronorm will fall into this group.
For the standard dosing principles and adjustment rules of Thyronorm, see the levothyroxine drug page.
What to Tell Your Doctor
If your doctor is reluctant to de-escalate, ask three specific questions:
- What criterion supports continuing Thyronorm? Are anti-TPO antibodies positive? Was TSH ever above 10? Am I pregnant? If none of these apply, the indication is weak.
- What is the harm of a monitored taper? Tapering with serial TSH monitoring carries minimal risk and high informational value.
- Will you support de-escalation if labs remain normal? This is the patient’s choice once the doctor explains risks.
Doctors who refuse all de-escalation conversation without engaging with the evidence are practising defensive medicine, not evidence-based care.
The Special Case of Older Adults
Subclinical hypothyroidism is more common in older adults, and the management is genuinely different from younger adults.
TSH drifts upward with age. A TSH of 5.5 in a 75-year-old is normal physiology, not disease. The Indian Thyroid Society 2021 consensus and US National Health and Nutrition Examination Survey both confirm that the 97.5th percentile of TSH rises to about 6.0 to 7.5 mIU/L in adults over 70.
The TRUST trial specifically showed no benefit of treatment in adults over 65. Pooled analyses suggest possible mild harm from treatment in this group — atrial fibrillation, fractures.
Practical rule for older adults:
| Age | Upper Limit of Normal TSH | When to Treat |
|---|---|---|
| Under 50 | 4.5 mIU/L | TSH above 10, or above 7 with positive anti-TPO and symptoms |
| 50 to 70 | 5.0 mIU/L | TSH above 10, or above 7 with positive anti-TPO and symptoms |
| Over 70 | 6.5 to 7.5 mIU/L | TSH above 10 with symptoms; rarely needed otherwise |
| Over 85 | Up to 7.5 mIU/L | Treatment threshold higher; avoid Thyronorm unless TSH above 12 |
Many older Indian patients are over-medicated based on younger-adult cutoffs. De-escalation is often the right answer.
Subclinical Hypothyroidism and Depression — The Treatment Trap
A common scenario: a patient presents with low energy, low mood, and weight gain. TSH is 5.8. The doctor starts Thyronorm and an SSRI together. Six months later, depression is unchanged.
This is one of the most common iatrogenic loops in Indian primary care. Subclinical hypothyroidism does not cause clinical depression; it is found incidentally in depressed patients because both are common. Treating the TSH does not treat the depression. Trials of levothyroxine augmentation in depression have shown mixed results, and most are negative for subclinical cases.
For the proper medical workup before psychiatric medication, see the depression guide — TSH and Free T4 belong in the workup, but a mildly elevated TSH should not be the explanation for major depressive disorder.
The Practical Decision Tree
Use this table to decide what to do with a TSH between 4.5 and 10.
| Your Situation | What to Do |
|---|---|
| Single TSH 4.5 to 7, no symptoms, no plans to conceive | Repeat in 6 to 8 weeks at same lab. Do not start treatment. |
| Repeat TSH 4.5 to 7, no symptoms, negative anti-TPO | Monitor every 6 to 12 months. No treatment. |
| Repeat TSH 4.5 to 7, no symptoms, positive anti-TPO | Monitor every 6 months. Counsel about progression risk. |
| TSH 7 to 10, positive anti-TPO, significant symptoms | Consider 3 to 6 month Thyronorm trial. Stop if no symptom response. |
| TSH above 10 on confirmed repeat | Start Thyronorm. |
| TSH 4.5 to 10, planning pregnancy in next 12 months | Treat to TSH under 2.5. |
| TSH 4.5 to 10, pregnancy first trimester | Treat to trimester-specific TSH cutoff. |
| TSH 4.5 to 10, infertility evaluation | Treat to TSH under 2.5. |
| TSH 4.5 to 10, age over 70, no symptoms | Do not treat. Re-evaluate annually. |
| TSH 4.5 to 10, on lithium for bipolar disorder | Treat. |
| TSH 4.5 to 10, history of thyroidectomy or radioiodine | Treat — likely under-replacement of known hypothyroidism. |
For lab assay differences that can move a borderline TSH across decision thresholds, see the lab comparison investigation.
What to Ask Your Doctor
If you have just been diagnosed with subclinical hypothyroidism or are being recommended Thyronorm, these are the questions worth asking.
- Was this TSH confirmed on a repeat test 6 to 8 weeks later? If not, ask for the repeat before starting medication.
- Was the sample drawn in the morning, before food, off biotin supplements? If not, the value may not reflect baseline.
- What was my Free T4? A normal Free T4 with elevated TSH is subclinical, not overt, hypothyroidism.
- Was anti-TPO tested? This changes the prognosis and the treatment decision.
- Am I in any of the specific scenarios that warrant treatment? Pregnancy planning, infertility, TSH above 10, significant symptoms with antibodies, lithium use, goitre.
- What is the evidence for starting Thyronorm at my specific TSH level? Ask about the TRUST trial and BMJ guidelines.
- If we start, when will we re-evaluate? Indefinite continuation should not be the default.
- Are there reversible factors that might have raised my TSH? Recent illness, biotin, lab assay drift, severe stress.
A doctor who engages with these questions is practising evidence-based medicine. A doctor who dismisses them and insists on immediate Thyronorm without these data is following habit, not evidence.
For when surgical intervention becomes relevant (large goitre, suspected malignancy), see the thyroidectomy procedure guide.
Sources & References
- Stott DJ et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med. 2017;376(26):2534-2544. (TRUST trial)
- Bekkering GE et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ. 2019;365:l2006.
- Mooijaart SP et al. Effect of Levothyroxine on Cardiovascular Events in Older Adults With Subclinical Hypothyroidism (IEMO 80-Plus). JAMA. 2019;322(20):1977-1986.
- Rodondi N et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365-1374.
- Pearce SHS et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013;2:215-228.
- Indian Thyroid Society. Position Statement on Subclinical Hypothyroidism in Indian Adults. 2021.
- Unnikrishnan AG et al. Prevalence of hypothyroidism in adults: An epidemiological study in eight cities of India. Indian J Endocrinol Metab. 2013;17(4):647-652.
- Alexander EK et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-389.
- Garber JR et al. Clinical Practice Guidelines for Hypothyroidism in Adults (AACE/ATA). Endocr Pract. 2012;18(6):988-1028.
- Floriani C et al. Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. Eur Heart J. 2018;39(7):503-507.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Subclinical hypothyroidism is a YMYL (Your Money or Your Life) topic that requires individualised clinical assessment by a qualified endocrinologist or general physician. The treatment thresholds, trial findings, and de-escalation protocols described here are based on Endocrine Society, American Thyroid Association, Indian Thyroid Society, and BMJ Rapid Recommendations guidelines as of 2026 and may change as new evidence emerges. Never start, stop, or adjust thyroid medication without medical supervision. Reviewed by healthcare professionals against published clinical guidelines and peer-reviewed trial data including the TRUST trial (NEJM 2017) and IEMO 80-Plus (JAMA 2019).